Syndax Pharmaceuticals, Inc.
Here’s whether Syndax Pharmaceuticals, Inc. (SNDX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.58% over 10 days); strong 1-year return of +38.3%; rising volume confirms the move (1.19x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); RSI 21 — oversold; 3-month momentum negative (-10.5%). Currently 25.3% off its 52-week high. Score: +2/7.
SNDX is holding above its long-term 200-day MA ($18.43) but has slipped below the 50-day MA ($22.91), pointing to short-term weakness in an otherwise intact trend. An RSI of 21.3 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +38.3% compares to +27.9% for SPY (beat the market by 10.4%). The current 25.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.